Unfortunately, shareholders of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) have suffered share price declines over the last year. To wit the share price is down 54% in that time. To make matters worse, ...

Wells Fargo launched its coverage of Sarepta Therapeutics (NASDAQ:SRPT) with an Overweight recommendation, citing commercial ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today shared updates ...

The past six months haven’t been great for Sarepta Therapeutics. It just made a new 52-week low of $52, and shareholders have ...

There are 956 funds or institutions reporting positions in Sarepta Therapeutics ... the author and do not necessarily reflect those of Nasdaq, Inc. Fintel is a leading provider of financial ...

In a report released today, Ritu Baral from TD Cowen maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report), with a price ...

(RTTNews) - Sarepta Therapeutics (SRPT ... views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New York ...

Shares of Sarepta Therapeutics declined after the EMA placed a clinical hold on all studies evaluating Elevidys, its one-shot gene therapy for Duchenne muscular dystrophy (DMD). This hold has been ...

As biotech investors know, companies in the industry can sometimes earn significant returns in relatively short periods, like a year, thanks to excellent clinical or regulatory progress. And based on ...

Sarepta Therapeutics (NASDAQ:SRPT) announced Friday that the company and its partner Roche (OTCQX:RHHBY) expect to provide EU ...

Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) was upgraded by investment analysts at HC Wainwright from a “sell” ...

Wells Fargo launched its coverage of Sarepta Therapeutics (NASDAQ:SRPT) with an Overweight recommendation, citing commercial prospects for Elevidys, a gene therapy developed by SRPT with Roche ...